Terran Biosciences

Thank you to @Psyched_Alpha for featuring Terran’s recently-granted composition-of-matter patent on #methylone in their recent review of the landscape. psychedelicalpha.com/news/february-… Terran’s patent covers the salts and polymorphs of racemic methylone HCl (US12,234,216B2), and these discoveries were the result of our team’s comprehensive salt and polymorph screening platform. We believe our IP covers the composition of matter of all of the developable forms of racemic methylone HCl. Methylone is a unique compound in that it is only able to form a few stable salts and polymorphs, all of which are covered by our IP portfolio, including fumarate, gentisate, maleate, citrate, tartrate, and freebase salts, as well as enantiomerically pure forms. With this granted patent we are in a strong position to defend our portfolio and continue the development of methylone for the treatment of psychiatric and neurological disorders. #mentalillness #PTSD #chemistry

We’re proud to announce that we’ve been granted a U.S. patent for the world’s first new polymorphs of #methylone hydrochloride (US-12234216-B2). Methylone is a rapid acting empathogen with a differentiated profile from MDMA and Terran is currently developing methylone as a potential treatment for #PTSD. This award represents the only granted composition of matter patent on the polymorphs of methylone hydrochloride and is a major milestone in our mission to make safe, affordable, and effective neuropsychiatric therapies more accessible to patients.

Terran CEO Sam Clark @neonneurons was recently featured on The BioHub podcast to discuss recent advances in #schizophrenia, including TerXT, our combination of novel prodrugs of xanomeline and trospium (the same active ingredients in FDA-approved Cobenfy) youtube.com/watch?v=OJQ2dg…

We are honored to receive BioTech Breakthrough’s Analytics Innovation of the Year award for NM-101, our FDA-cleared software platform to analyze neuromelanin MRI scans. biotechbreakthroughawards.com/2024-winners/ With this new technology we aim to aid in the evaluation of complex neuropsychiatric conditions like #ParkinsonsDisease. We are grateful to be featured alongside the other award winners, and hope to continue to bring groundbreaking innovations like NM-101 to patients in need.

The Terran team is thrilled to have been selected as a Fierce Life Science Innovation Award finalist for our FDA-approved NM-101 software technology to aid in the evaluation of #ParkinsonsDisease and other neuropsychiatric conditions. We are honored to be recognized alongside the other pioneers in the medical device space. …novationawards.fiercelifesciences.com/fiercelifescie… #FierceLifeSciencesAwards #FierceInnovationAwards

Terran's CEO Sam Clark @neonneurons moderated an @HCPLiveNews panel alongside key opinion leaders Dr. Andrew Cutler and Dr. Rishi Kakar (lead investigator on the KarXT trials), to discuss the FDA approval of KarXT (Cobenfy) for #schizophrenia, and what this means for patients and future therapeutics.

As a global leader in psychedelic manufacturing and supply, Terran is excited to provide psilocybin, LSD, and DMT, to Gitte Moos Knudsen’s lab at @CopenhagenNeuro to support their groundbreaking research in psychiatry and neurology. These are some of the many psychedelic compounds Terran is providing to researchers and clinics.

Terran’s CEO Sam Clark @neonneurons connected with @kellyb720 at @pharmavoice for her article alongside @KarunaTx founder Andrew Miller to discuss the recent FDA approval of KarXT (Cobenfy) for #schizophrenia and future innovations like TerXT. pharmavoice.com/news/bms-karxt…

Terran CEO Sam Clark @neonneurons shared his thoughts on what the FDA’s recent approval of KarXT (Cobenfy) means for #schizophrenia patients and for new innovation in this article by @MelissaRudy at @FoxNews alongside commentary by @bmsnews CEO: foxnews.com/health/new-sch…

Today at 10:00am ET, Terran’s founder and CEO, Sam Clark, MD PhD @neonneurons will be presenting on our unique prodrug approach to create novel therapeutics like TerXT for the treatment of #schizophrenia. Register for the webinar below:

Late last night the FDA announced they had approved the new #schizophrenia drug Cobenfy (formerly KarXT). Terran CEO Sam Clark @neonneurons spoke with @ChelsieDerman at @HCPLiveNews, and shared his thoughts on this big win for patients and the implications for new innovation.